Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason M Pogue

Showing results (81-90 of 167) with videos related to

Pageof 17
Sort By:
Journal of Infection and Public Health|November 12, 2013
Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare systemFarah Ahmad, Jason M Pogue, Dror Marchaim, et al.
Antimicrobial Agents and Chemotherapy|November 1, 2017
Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous VancomycinEvan J Zasowski, Kyle P Murray, Trang D Trinh, et al.
Open Forum Infectious Diseases|July 16, 2020
Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming PatientsPaul G Ambrose, Sujata M Bhavnani, David R Andes, et al.
Open Forum Infectious Diseases|June 6, 2020
The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot InfectionsOryan Henig, Jason M Pogue, Emily Martin, et al.
Infectious Diseases and Therapy|October 23, 2019
Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's ComplicatedJessica K Ortwine, Evan J Zasowski, Jason M Pogue, et al.
Pharmacotherapy|September 20, 2011
Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelinesRavina Kullar, Steven N Leonard, Susan L Davis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2025
First report of treatment-emergent resistance to cefepime-zidebactam in Pseudomonas aeruginosaAva J Dorazio, Samuel L Aitken, Virginia M Pierce, et al.
Antimicrobial Agents and Chemotherapy|April 26, 2017
Critical Need for Clarity in Polymyxin B DosingNikolas J Onufrak, Gauri G Rao, Alan Forrest, et al.
The Journal of Antimicrobial Chemotherapy|September 7, 2018
Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patientSarah C J Jorgensen, Philip McDonald, Ryan P Mynatt, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 24, 2012
Growing prevalence of Providencia stuartii associated with the increased usage of colistin at a tertiary health care centerKayoko Hayakawa, Dror Marchaim, George W Divine, et al.
Pageof 17

Showing results (81-90 of 167) with videos related to

Sort By:
Pageof 17
Journal of Infection and Public Health|November 12, 2013
Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare systemFarah Ahmad, Jason M Pogue, Dror Marchaim, et al.
Antimicrobial Agents and Chemotherapy|November 1, 2017
Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous VancomycinEvan J Zasowski, Kyle P Murray, Trang D Trinh, et al.
Open Forum Infectious Diseases|July 16, 2020
Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming PatientsPaul G Ambrose, Sujata M Bhavnani, David R Andes, et al.
Open Forum Infectious Diseases|June 6, 2020
The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot InfectionsOryan Henig, Jason M Pogue, Emily Martin, et al.
Infectious Diseases and Therapy|October 23, 2019
Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's ComplicatedJessica K Ortwine, Evan J Zasowski, Jason M Pogue, et al.
Pharmacotherapy|September 20, 2011
Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelinesRavina Kullar, Steven N Leonard, Susan L Davis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2025
First report of treatment-emergent resistance to cefepime-zidebactam in Pseudomonas aeruginosaAva J Dorazio, Samuel L Aitken, Virginia M Pierce, et al.
Antimicrobial Agents and Chemotherapy|April 26, 2017
Critical Need for Clarity in Polymyxin B DosingNikolas J Onufrak, Gauri G Rao, Alan Forrest, et al.
The Journal of Antimicrobial Chemotherapy|September 7, 2018
Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patientSarah C J Jorgensen, Philip McDonald, Ryan P Mynatt, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 24, 2012
Growing prevalence of Providencia stuartii associated with the increased usage of colistin at a tertiary health care centerKayoko Hayakawa, Dror Marchaim, George W Divine, et al.
Pageof 17